{"id":"prabotulinumtoxina-xvfs","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Injection site reactions (erythema, edema, bruising)"},{"rate":"1-5","effect":"Headache"},{"rate":"1-3","effect":"Muscle weakness or drooping"},{"rate":"<1","effect":"Eyelid ptosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug is a purified botulinum toxin serotype A that cleaves SNARE proteins required for acetylcholine vesicle release. By preventing neurotransmitter release at motor nerve terminals, it induces temporary flaccid paralysis of injected muscles. The effect is reversible as new neuromuscular junctions form over several months.","oneSentence":"PrabotulinumtoxinA-Xvfs is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:02:09.304Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Aesthetic treatment of facial wrinkles and expression lines"},{"name":"Cosmetic facial rejuvenation"}]},"trialDetails":[{"nctId":"NCT06604832","phase":"PHASE1","title":"Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture","status":"COMPLETED","sponsor":"Kalpna Kay Durairaj, MD, FACS","startDate":"2024-09-03","conditions":"Skin Aging, Skin Wrinkling","enrollment":20},{"nctId":"NCT06903975","phase":"PHASE4","title":"BoTox Into the Sternocleidomastoid Muscles (SCM)","status":"RECRUITING","sponsor":"Boston Medical Center","startDate":"2025-05-14","conditions":"Neck Muscle Issue","enrollment":30},{"nctId":"NCT05320393","phase":"PHASE2","title":"Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines","status":"COMPLETED","sponsor":"Evolus, Inc.","startDate":"2022-03-30","conditions":"Glabellar Frown Lines","enrollment":154},{"nctId":"NCT05807412","phase":"EARLY_PHASE1","title":"Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides","status":"COMPLETED","sponsor":"Lupo Center for Aesthetic and General Dermatology","startDate":"2023-05-01","conditions":"Rhytides","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Jeaveau","Jeuveau"],"phase":"marketed","status":"active","brandName":"PrabotulinumtoxinA-Xvfs","genericName":"PrabotulinumtoxinA-Xvfs","companyName":"Lupo Center for Aesthetic and General Dermatology","companyId":"lupo-center-for-aesthetic-and-general-dermatology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PrabotulinumtoxinA-Xvfs is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Aesthetic treatment of facial wrinkles and expression lines, Cosmetic facial rejuvenation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}